With nearly 6,000 reported cholera cases, including more than 100 deaths, Guinea is facing the worst cholera outbreak since 2007, and “some residents of the capital Conakry are clamoring to be vaccinated,” IRIN reports. “The cholera vaccine has shown promising results in the handful of communities where it has been used: none of those vaccinated have been infected,” the news service writes, noting, “For now cholera vaccination is not generally done on a large scale.” According to IRIN, “WHO and partner agencies are planning a cholera vaccine stockpile for epidemic control and looking at the possibility of introducing the two-dose oral vaccine into national immunization programs in endemic areas,” but the agency also “says such stockpiles should not detract from other prevention efforts: detection, diagnosis, and treatment of cases with oral rehydration and antibiotics; establishment of a safe water supply; implementation of adequate waste disposal, sanitation, and hygiene; and communication and social mobilization.”
Private Sector Involvement
The Affordable Medicines Facility-malaria (AMFm) — an innovative financing mechanism that subsidizes the cost of artemisinin-based combination therapies (ACTs) in order to expand access to the most effective treatment for malaria — “brought more than 100 million doses of malaria drugs to clinics and pharmacies in 2011” and “also increased access to the top malaria medicines by 26 to 52 percent in six countries,” according to results from the first phase of the program, which is hosted and managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria, NPR’s “Shots” blog reports. The results of the evaluation, released on Wednesday in Washington, D.C., do not estimate how many lives were saved because of improved access to effective malaria medications, as “AMFm ran for only a year and half in most countries,” according to the blog. “The AMFm negotiated with drugmakers to reduce ACTs prices, and then the Global Fund subsidized the initial purchasing of the drugs by clinics and pharmacies,” the blog notes.
French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance “to accelerate the discovery and development of novel compounds against tuberculosis,” RTTNews reports (9/20). “According to company material, the projects will explore a compound which researchers believe has potential to treat all forms of tuberculosis, investigate another class of natural derivatives that has shown ‘impressive’ activity against tuberculosis bacteria, and identify future candidates for development among chemical compounds in Sanofi’s collection,” the Center for Global Health Policy’s “Science Speaks” blog writes (Barton, 9/20). RTTNews notes, “Sanofi, which discovered rifampicin in the early 1960s, markets several anti-tuberculosis drugs” (9/20).
The Coca-Cola Company and the Global Fund to Fight AIDS, Tuberculosis and Malaria have announced the expansion of a pilot project, called “Project Last Mile,” that uses Coca Cola’s “‘expansive global distribution system and core business expertise’ to help deliver critical medicines to remote parts of the world, beginning in rural Africa,” Pharma Times reports. “The public-private partnership was established in 2010 to help Tanzania’s government-run medicine distribution network, Medical Stores Department, build a more efficient supply chain by using Coca-Cola’s” delivery system model, the news service writes, adding, “The latest phase of the partnership, developed in cooperation with the likes of the Bill & Melinda Gates Foundation, Accenture and Yale University, will increase the availability of critical medicines to 75 percent of Tanzania and expand the initiative to Ghana and Mozambique” (Grogan, 9/26).
“India has had a positive global impact through its supply of vast quantities of low-cost, good-quality generic medicines, which have saved or prolonged millions of lives … [b]ut there are also many factors that may hinder the continuation of the [country's] role as chief supplier of medicines to developing countries,” Martin Khor, executive director of the South Centre in Geneva, writes in an Inter Press Service opinion piece. He examines the history of generic drug production in India and says the 1995 World Trade Organization TRIPS agreement negatively affected the country’s ability to produce generic drugs. Though “India has one of the best patent laws in the world that still gives some space to its producers to make generic drugs, … it is also true that the old policy space has been eroded because many new drugs have, since 2005, been patented by multinational companies that are selling them at exorbitant prices,” Khor writes.
“The worldwide counterfeit drug market is huge and growing,” Tim Mackey and Brian Liang of the Institute of Health Law Studies at the California Western School of Law and Thomas Kubic of the Pharmaceutical Security Institute write in a Foreign Policy opinion piece, noting such “drugs occupy a wide spectrum of medications, and their quality is suspect; they can be mislabeled, tainted, adulterated, ineffective, or, in the worst cases, all of the above.” They argue for a new framework for fighting the illegal drug trade because “[g]lobal policy has not kept up with the burgeoning counterfeit drug trade.” The authors say that although initial results of the WHO IMPACT (International Medical Products Anti-Counterfeit Taskforce) are “encouraging,” they note that “[s]ome WHO member states, including India and Brazil (both top producers of generic drugs) and other developing countries, have questioned whether WHO can rightly take on enforcement operations” because it “is not a global law enforcement agency.”
In a post on USAID’s “IMPACTblog,” Amanda Makulec of John Snow Inc. describes the Helping Babies Breathe (HBB) initiative, which was developed “to equip birth attendants in developing countries with the skills they need to successfully resuscitate babies born without the ability to breathe on their own.” She continues, “[I]t was the power of the Global Development Alliance (GDA) model — public-private partnership on a global scale — that dramatically expanded access to newborn resuscitation in remote health facilities and communities in 34 countries within 18 months of the launch of the partnership … by leveraging the commitment, resources, and support of a diverse group of program implementers, NGOs, private sector organizations, government institutions, U.N. agencies, professional associations to enable the rapid roll out of the intervention globally” (4/30).
The Center for Global Health Policy’s “Science Speaks” blog notes that PEPFAR recently released its 8th annual report (.pdf) to Congress. “The five-page document outlines the program’s progress as of the end of fiscal year 2011 in various areas,” including the provision of antiretroviral treatment, care, and support; HIV testing and counseling for pregnant women; and prevention of mother-to-child transmission services, the blog notes. The report includes sections on “leading with science,” “smart investments,” “country ownership,” and “shared responsibility,” according to the blog (Mazzotta, 5/4).
In this article on the Feed the Future initiative’s webpage, Tjada McKenna, deputy coordinator for development for Feed the Future, and Jonathan Shrier, acting special representative for global food security and deputy coordinator for diplomacy for Feed the Future, ask and answer five questions about the New Alliance for Food Security and Nutrition, launched last week by the Obama Administration. The authors discuss the participants in the initiative, the specific commitments of these participants, as well as the costs of the initiative (5/23).
GlobalPost reports on the GBCHealth Conference, which took place in New York City on Monday and where “panelists at a session titled ‘AIDS@30’ were asked how they would fulfill U.S. Secretary of State Hillary Clinton’s call late last year for an ‘AIDS-free generation.’” According to the news service, “Ambassador Eric Goosby, the U.S. global AIDS coordinator, said the key will likely be a combination HIV prevention strategy” that “includes expansion of treatment to help prevent new infections; major scale-up of male circumcision; and treating all HIV-positive pregnant women to end the transmission of HIV from mother to child.” GlobalPost adds, “Michel Sidibe, UNAIDS executive director, said the way to defeat AIDS had to include more financial contributions from developing countries.” GlobalPost quotes several other conference attendees (Donnelly, 5/15).